Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of REGENXBIO in a note issued to investors on ...

Analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Sutro Biopharma in a research note issued ...

H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report.

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Femasys (FEMY) to $15 from $12 and keeps a Buy rating ...

H.C. Wainwright analyst Edward White maintained a Hold rating on Avalo Therapeutics (AVTX – Research Report) today. The company’s shares opened ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

H.C. Wainwright analyst Mike Colonnese says the recent selloff in the bitcoin miners “has created a very attractive buying opportunity.” Macro ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: ...

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...

In a report released today, Kevin Dede from H.C. Wainwright maintained a Hold rating on Biotricity (BTCY – Research Report). The company’s shares closed last Friday at $0.50.

Detailed price information for Marker Therapeutics Inc (MRKR-Q) from The Globe and Mail including charting and trades.